Standout Papers

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (S... 2017 2026 2020 2023 428
  1. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial (2017)
    Andrew Ahmann, Matthew Capehorn et al. Diabetes Care

Immediate Impact

2 by Nobel laureates 14 from Science/Nature 66 standout
Sub-graph 1 of 17

Citing Papers

Diabetes mellitus—Progress and opportunities in the evolving epidemic
2024 Standout
Transforming obesity: The advancement of multi-receptor drugs
2024 Standout
3 intermediate papers

Works of G. Charpentier being referenced

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
2018
Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin
2004
and 3 more

Author Peers

Author Last Decade Papers Cites
G. Charpentier 3549 2079 1722 150 6.0k
David R. Owens 6222 2018 2699 269 9.8k
Linong Ji 4329 1694 1416 239 7.0k
Seung‐Hyun Ko 2962 1519 1649 245 6.4k
Motoaki Shichiri 2723 1460 1357 125 5.7k
Yogish C. Kudva 3255 1104 3693 174 7.0k
Stéphan Martin 1869 1055 1066 157 6.2k
Jean‐Louis Chiasson 4344 1742 1207 82 6.6k
Ronan Roussel 2618 1364 1383 229 5.8k
Bruno Guerci 3518 1286 1590 203 4.9k
R R Holman 5379 1417 1338 48 7.4k

All Works

Loading papers...

Rankless by CCL
2026